Kevzara Insurance Denied? How to Appeal Your Sarilumab Denial

Kevzara (sarilumab) is an IL-6 receptor inhibitor approved for moderate-to-severe active rheumatoid arthritis in adults who have had an inadequate response to one or more DMARDs. A fully human monoclonal antibody, Kevzara can be used as monotherapy or in combination with methotrexate or other conventional DMARDs. Despite its clinical effectiveness, insurance denials for Kevzara are common — often due to step therapy requirements or formulary preferences for its competitor, Actemra (tocilizumab). Here's how to fight back.

What Kevzara Treats and Why Patients Need It

Kevzara blocks both the membrane-bound and soluble forms of the IL-6 receptor, interrupting the signaling pathway that drives joint inflammation, systemic inflammation, and progressive joint destruction in RA.

In clinical trials (MOBILITY, TARGET), Kevzara demonstrated:

• Significant reduction in signs and symptoms of RA compared to placebo
• Prevention of joint structural damage (radiographic progression)
• Improvement in physical function
• Effectiveness as monotherapy in patients who couldn't tolerate methotrexate

For RA patients who have failed TNF inhibitors or conventional DMARDs and need a different mechanism of action, Kevzara provides an important therapeutic option.

Why Insurers Deny Kevzara

Step therapy / TNF inhibitor requirement: Most plans require failure of one or more TNF inhibitors before approving an IL-6 inhibitor. This reflects a traditional RA treatment algorithm, though clinical guidelines increasingly support considering IL-6 inhibitors earlier in certain patients.

DMARD failure not adequately documented: Plans require demonstrated failure of methotrexate (and often leflunomide or other DMARDs) before any biologic. Incomplete documentation of DMARD trials is a common reason for denial.

Preferred IL-6 inhibitor (Actemra) not tried: Some plans prefer Actemra (tocilizumab) over Kevzara and require a trial of Actemra before approving Kevzara.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization not submitted correctly: Missing documentation of disease activity scores, prior treatments, or indication-specific requirements.

Not covered for monotherapy: Some plans may have coverage criteria requiring combination with methotrexate, even though Kevzara is FDA-approved for monotherapy.

Step-by-Step: How to Appeal a Kevzara Denial

Step 1: Identify the denial reason precisely. Step therapy, formulary preference, insufficient documentation?

Step 2: Document your RA treatment history. List every conventional DMARD tried: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine. Include dose, duration, and reason for failure (insufficient efficacy, adverse effects, contraindication).

Step 3: Document prior biologic history if applicable. If you've tried TNF inhibitors (Humira, Enbrel, Remicade, etc.) and failed, document this with specific details.

Step 4: Document current disease activity. DAS28-CRP or DAS28-ESR, CDAI, or SDAI scores quantifying disease severity and inadequate response to current therapy.

Step 5: Have your rheumatologist write a Letter of Medical Necessity addressing your RA diagnosis, disease activity, prior treatment history, and why sarilumab is the appropriate next step.

Step 6: If denied in favor of Actemra, document the reason for selecting Kevzara specifically. Prior intolerance of Actemra, previous failure of Actemra, or a clinical reason for the subcutaneous formulation only (Kevzara is SC only; Actemra is available IV and SC).

Step 7: Submit the internal appeal and request peer-to-peer review.

Step 8: File an external appeal if the internal appeal is denied.

What to Include in Your Kevzara Appeal Letter

• Member information, policy number, and claim reference
• Kevzara (sarilumab) prescribed dose and indication
• Current disease activity score (DAS28, CDAI, or SDAI)
• HAQ (Health Assessment Questionnaire) functional score if available
• Conventional DMARD history: drugs, doses, durations, and outcomes
• Prior biologic history with outcomes
• If methotrexate intolerance: reason sarilumab monotherapy is appropriate
• Letter of Medical Necessity from rheumatologist
• ACR RA treatment guideline citation supporting IL-6 inhibitor use after DMARD/TNF failure
• Clinical reason for sarilumab over formulary-preferred alternatives if applicable
• Request for peer-to-peer review

Success Tips for Kevzara Appeals

Show a progression of treatment. A well-documented treatment timeline — from methotrexate, to TNF inhibitor, to now needing an IL-6 inhibitor — demonstrates that you haven't jumped straight to the most expensive option. This historical arc is compelling for any reviewer.

Quantify persistent disease activity. A current DAS28 score in the moderate-to-high range (≥3.2 on conventional DMARD or prior biologic therapy) shows that your disease remains inadequately controlled despite appropriate treatment.

Use the monotherapy option if MTX isn't tolerated. Kevzara's approval as monotherapy is important for patients who cannot take methotrexate due to liver disease, lung disease, severe nausea, or other adverse effects. Document MTX intolerance clearly.

Highlight rapid onset of action. Kevzara demonstrates early clinical response, which is relevant for patients with high disease activity affecting daily function, work, and quality of life.

Include functional impact. HAQ scores, work disability, joint deformity, and inability to perform activities of daily living are important components of the medical necessity argument.

Fight Back With ClaimBack

Rheumatoid arthritis is a progressive, disabling disease. If your insurer denied Kevzara, ClaimBack can help you mount a comprehensive, evidence-based appeal to fight for the treatment your rheumatologist prescribed.

Start your Kevzara appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied